Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Dario Cattaneo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Pathology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Drug Monitoring, Body Mass Index. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.
Abstract (Originalsprache)
Background
Recently, we documented that proactive therapeutic drug monitoring (TDM) allowed the successful individualization of the timing of dalbavancin administration in patients requiring prolonged antibiotic treatment. Here, we aimed to identify variables associated with the timing of TDM-guided dalbavancin dosing in patients who underwent proactive dalbavancin TDM.
Methods
Adult patients who received at least three 1500 mg doses of dalbavancin for osteoarticular infections were included in the study. Univariate and multivariate linear regression analyses were performed, considering the timing of dalbavancin administrations as the dependent variable and clinical features as dependent covariates.
Results
Sixty-three patients [65% male, mean (SD) age 64 ± 16 years] fulfilling the inclusion criteria were included in the study. Patients were given a mean (SD) 6.4 ± 5.0 injections of dalbavancin over a mean (SD) period of 198 ± 213 days. Dalbavancin was administered every 40 ± 7 days (range:16–71 days). By univariate linear regression analyses, patient age (P = 0.002), BMI (P < 0.001), serum albumin (P = 0.011) and the duration of dalbavancin treatment (P = 0.012) was found to be associated with the timing of dalbavancin administration. The BMI was the only variable retained in the final multivariate model (P < 0.001). A highly significant reduction in timing of dalbavancin administration was observed between patients with obesity, overweight and normal weight [mean (SD) 30 ± 7 versus 38 ± 4 versus 43 ± 7 days].
Conclusions
Overweight and obesity significantly impacted on dalbavancin pharmacokinetics in patients with osteoarticular infections requiring prolonged antibiotic treatment. These effects can be handled by proactive TDM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Clinical Pathology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.
- Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
ORCID-Profile: Dario Cattaneo, Sarah Birindelli
Förderung
- the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
Zitieren
APA
Cattaneo, D., Fusi, M., Mariani, C., Passerini, M., Scandiffio, L., Birindelli, S., Merli, S., Giorgi, R., Gori, A., & Dolci, A. (2025). Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf132
Vancouver
Cattaneo D, Fusi M, Mariani C, Passerini M, Scandiffio L, Birindelli S, et al. Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf132
BibTeX
@article{Cattaneo2025,
author = {Cattaneo, Dario and Fusi, Marta and Mariani, Chiara and Passerini, Matteo and Scandiffio, Letizia and Birindelli, Sarah and Merli, Stefania and Giorgi, Riccardo and Gori, Andrea and Dolci, Alberto},
title = {Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf132}
}
EUVIMED